FibroGen's third quarter 2025 results highlight significant corporate transformations with the successful sale of FibroGen China for $220 million, extending the company's financial runway into 2028 and paving the way for advancing its promising oncology pipeline.

• Completed the sale of FibroGen China to AstraZeneca for approximately $220 million, enhancing liquidity and eliminating debt obligations.
• Progressed with FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer (mCRPC), initiating a Phase II trial and anticipating key trial results in early 2026.
• Clear regulatory pathway established for roxadustat's Phase III trial submission for lower-risk myelodysplastic syndromes, enhancing the company's therapeutic potential.
• FG-3246 shows promising early results, with notable radiographic progression-free survival and response rates in heavily pretreated mCRPC patients.